Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 37Carcinoma, Hepatocellular 20Neoplasm Metastasis 19Lung Neoplasms 19Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Stomach Neoplasms 15Colorectal Neoplasms 15Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 10Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Colonic Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Basal Cell 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Sarcoma 5

Interventions

pembrolizumab 4atezolizumab 3Cetuximab 3olaparib 2Trastuzumab 2Docetaxel 2zimberelimab 1tocilizumab 1spartalizumab 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1ipatasertib 1inavolisib 1fludarabine phosphate 1fludarabine 1entrectinib 1encorafenib 1cemiplimab 1binimetinib 1anlotinib 1amivantamab 1alectinib 1adagrasib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Nivolumab × 90 days × Clear all
NCT07176975 2026-05-26

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Boehringer Ingelheim

Phase 1 Not yet recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡